A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden

被引：3

作者：

Rebeck, Olivia N. ^{[1
,2
]}

Wallace, Miranda J. ^{[1
,2
]}

Prusa, Jerome ^{[1
,2
]}

Ning, Jie ^{[1
,2
]}

Evbuomwan, Esse M. ^{[1
,2
,3
]}

Rengarajan, Sunaina ^{[1
,4
]}

Habimana-Griffin, Lemoyne ^{[1
,5
]}

Kwak, Suryang ^{[1
,2
]}

Zahrah, David ^{[1
]}

Tung, Jason ^{[1
]}

Liao, James ^{[1
,2
]}

Mahmud, Bejan ^{[1
,2
]}

Fishbein, Skye R. S. ^{[1
,2
]}

Tovar, Erick S. Ramirez ^{[1
,2
]}

Mehta, Rehan ^{[1
,2
]}

Wang, Bin ^{[1
,2
]}

Gorelik, Mark G. ^{[1
,2
]}

Helmink, Beth A. ^{[6
]}

Dantas, Gautam ^{[1
,2
,3
,7
,8
]}

机构：

[1] Washington Univ, Sch Med, Edison Family Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA

[3] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA

[4] Washington Univ, Sch Med, John T Milliken Dept Internal Med, Div Dermatol, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[7] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA

[8] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA

来源：

CELL CHEMICAL BIOLOGY | 2025年 / 32卷 / 01期

基金：

美国国家卫生研究院;

关键词：

MONOCLONAL-ANTIBODY THERAPY; SACCHAROMYCES-BOULARDII; GUT MICROBIOME; RESISTANCE; CANCER; IMMUNOTHERAPY; MECHANISMS; PREVENTION; EFFICACY;

D O I：

10.1016/j.chembiol.2024.10.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Engineered probiotics are an emerging platform for in situ delivery of therapeutics to the gut. Herein, we developed an orally administered, yeast-based therapeutic delivery system to deliver next-generation immune checkpoint inhibitor (ICI) proteins directly to gastrointestinal tumors. We engineered Saccharomyces cerevisiae var. boulardii (Sb), a probiotic yeast with high genetic tractability and innate anticancer activity, to secrete "miniature"antibody variants that target programmed death ligand 1 (Sb_haPD-1). When tested in an ICI-refractory colorectal cancer (CRC) mouse model, Sb_haPD-1 significantly reduced intestinal tumor burden and resulted in significant shifts to the immune cell profile and microbiome composition. This oral therapeutic platform is modular and highly customizable, opening new avenues of targeted drug delivery that can be applied to treat a myriad of gastrointestinal malignancies.

引用

页数：21

共 50 条

[1] The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, Camille
Bakhl, Katrina
Georgakopoulos-Soares, Ilias
Zaravinos, Apostolos
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
[2] Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
Lee, Se-Hoon
Cho, Sung-Yup
Yoon, Youngmin
Park, Changho
Sohn, Jinyoung
Jeong, Jin-Ju
Jeon, Bu-Nam
Jang, Mongjoo
An, Choa
Lee, Suro
Kim, Yun Yeon
Kim, Gihyeon
Kim, Sujeong
Kim, Yunjae
Lee, Gwang Bin
Lee, Eun Ju
Kim, Sang Gyun
Kim, Hong Sook
Kim, Yeongmin
Kim, Hyun
Yang, Hyun-Suk
Kim, Sarang
Kim, Seonggon
Chung, Hayung
Moon, Myeong Hee
Nam, Myung Hee
Kwon, Jee Young
Won, Sungho
Park, Joon-Suk
Weinstock, George M.
Lee, Charles
Yoon, Kyoung Wan
Park, Hansoo
NATURE MICROBIOLOGY, 2021, 6 (03) : 277 - +
[3] Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
Se-Hoon Lee
Sung-Yup Cho
Youngmin Yoon
Changho Park
Jinyoung Sohn
Jin-Ju Jeong
Bu-Nam Jeon
Mongjoo Jang
Choa An
Suro Lee
Yun Yeon Kim
Gihyeon Kim
Sujeong Kim
Yunjae Kim
Gwang Bin Lee
Eun Ju Lee
Sang Gyun Kim
Hong Sook Kim
Yeongmin Kim
Hyun Kim
Hyun-Suk Yang
Sarang Kim
Seonggon Kim
Hayung Chung
Myeong Hee Moon
Myung Hee Nam
Jee Young Kwon
Sungho Won
Joon-Suk Park
George M. Weinstock
Charles Lee
Kyoung Wan Yoon
Hansoo Park
Nature Microbiology, 2021, 6 : 277 - 288
[4] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
Nandakumar, Vijayalakshmi
Mills, John R.
CLINICAL CHEMISTRY, 2019, 65 (02) : 357 - 357
[5] Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Gerber, D.
Popat, V.
Lu, R.
Saltarski, J.
Gloria-Mccutchen, Y.
Fattah, F.
Park, J.
Xie, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S469 - S469
[6] Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math
Frank A. Giordano
Marlon R. Veldwijk
Carsten Herskind
Frederik Wenz
Strahlentherapie und Onkologie, 2018, 194 : 873 - 875
[7] Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma
Shrestha, R.
Prithviraj, P.
Bridle, K. R.
Crawford, D. H. G.
Anaka, M.
Jayachandran, A.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 31 - 31
[8] Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math
Giordano, Frank A.
Veldwijk, Marlon R.
Herskind, Carsten
Wenz, Frederik
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (10) : 873 - 875
[9] Yeast-based vaccine induces immune responses and reduces tumor size in mice
Lang, Les
GASTROENTEROLOGY, 2008, 135 (03) : 722 - 723
[10] The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review
Wang, Dan
Hao, He
Li, Xing
Wang, Zhiyu
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)

← 1 2 3 4 5 →